1-4 of 4
Monika Wroclawska, MD
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Adore: A Randomized, Open-Label, Phase 1/2 Open-Platform Study Evaluating Safety and Efficacy of Novel Ruxolitinib Combinations in Patients with Myelofibrosis

Andrew Charles Perkins, MBBS,PhD, Kate Burbury, MBBS, FRACP, FRCPA, DPhil, Thomas Lehmann, MD, David M Ross, MBBS, PhD FRACP, FRCPA, Andreas Reiter, MD, Vikas Gupta, MD FRCP, FRCPath, Claire Harrison, DM, FRCP, FRCPath, Jean-Jacques Kiladjian, MD PhD, Alessandro M. Vannucchi, MD, Marielle Wondergem, MD, Robert Pack, PhD, Monika Wroclawska, MD, Celine Wilke, MD, Angela Zhang, PhD, Florian H. Heidel, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 52–53.
https://doi.org/10.1182/blood-2020-140408
Published: 2020
Journal Articles

The Final Analysis of Expand: A Phase 1b, Open-Label, Dose-Finding Study of Ruxolitinib (RUX) in Patients (pts) with Myelofibrosis (MF) and Low Platelet (PLT) Count (50 × 10 9 /L to < 100 × 10 9 /L) at Baseline

Paola Guglielmelli, MD, Jean-Jacques Kiladjian, MD PhD, Alessandro M. Vannucchi, MD, Ming-hui Duan, MD, Haitao Meng, MD PhD, Ling Pan, MD PhD, Guangsheng He, MD PhD, Srdan Verstovsek, MD PhD, Françoise Boyer-Perrard, MD, Fiorenza Barraco, MD, Dietger Niederwieser, MD PhD, Anna Marina Liberati, MD, Claire Harrison, DM, FRCP, FRCPath, Pantelia Roussou, MSc, Monika Wroclawska, MD, Kevin Majidi, Peter AW te Boekhorst, MD PhD, Heinz Gisslinger, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 4–5.
https://doi.org/10.1182/blood-2020-137742
Published: 2020
Journal Articles

Ruxolitinib for Patients (Pts) with Polycythemia Vera: Responders Vs Non-Responders As Defined in the Response Trial

Srdan Verstovsek, MD PhD, Jean-Jacques Kiladjian, MD PhD, Monika Wroclawska, MD, Tuochuan Dong, Alessandro M. Vannucchi, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 2947.
https://doi.org/10.1182/blood-2019-128101
Published: 2019
Journal Articles

Long-Term Efficacy and Safety (5 Years) in RESPONSE, a Phase 3 Study Comparing Ruxolitinib (rux) with Best Available Therapy (BAT) in Hydroxyurea (HU)-Resistant/Intolerant Patients (pts) with Polycythemia Vera (PV)

Jean-Jacques Kiladjian, MD PhD, Pierre Zachée, Masayuki Hino, MDPhD, Fabrizio Pane, Tamas Masszi, MD Prof., Claire N. Harrison, MD DM, FRCP, PRCPath, Ruben A. Mesa, MD, Carole B. Miller, MD, Francesco Passamonti, MD, Simon Durrant, FRCP,FRCPath,MBBS, Martin Griesshammer, MD PhD, Keita Kirito, MD, Carles Besses, MD PhD, Beatriz Moiraghi, Elisa Rumi, MD, Vittorio Rosti, MD, Igor W. Blau, Nathalie Francillard, Tuochuan Dong, Monika Wroclawska, MD, Alessandro M. Vannucchi, MD, Srdan Verstovsek, MD PhD
Journal: Blood
Blood (2018) 132 (Supplement 1): 1753.
https://doi.org/10.1182/blood-2018-99-115129
Published: 2018